Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

HTDS announces recent business developments

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) brings attention to a certain previously released news announcements namely January 7 2009, November 19, 2009, Dec 15, 2009 January 12,2010, and January 22, 2010.

6 Feb 2010

Study calls for individualized therapeutic interventions for MS patients

Fewer African Americans than Caucasians develop multiple sclerosis (MS), statistics show, but their disease progresses more rapidly, and they don't respond as well to therapies, a new study by neurology researchers at the University at Buffalo has found.

6 Feb 2010

New ICD-9-CM database provides FDA-approved and off-label uses for therapeutic drugs

A recently released Drug Diagnosis Coding database from RJ Health Systems provides accurate FDA-approved and Compendia-listed off-label uses for therapeutic classes such as Oncology, Anti-Emetics, Erythropoietin Stimulating Agents and Multiple Sclerosis Agents. The

5 Feb 2010

Immigrants may be healthier than long-term residents

New immigrants to North America may be less likely to have a stroke at a young age than long-time residents, according to a study published in the February 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Feb 2010

Low Vision of Michigan introduces new device for RP patients

To commemorate Low Vision Awareness Month this February, Dr. Sheldon Smith, optometrist at Low Vision of Michigan, P.C., is offering free evaluations to patients diagnosed with retinitis pigmentosa (RP), a leading cause of low vision, in hopes that they might be candidates for a brand-new device designed to enhance or restore sight.

4 Feb 2010

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

As the third annual, worldwide Purple Day for Epilepsy approaches on March 26, 2010, organizers in Canada and in 15 other participating countries around the globe are looking for volunteers to promote epilepsy awareness in local communities.

3 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.

3 Feb 2010

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Compugen Ltd. announced today the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders.

2 Feb 2010

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response.

2 Feb 2010

Memory loss or decline in thinking abilities may indicate higher risk of stroke

People who experience memory loss or a decline in their thinking abilities may be at higher risk of stroke, regardless of whether they have been diagnosed with dementia, according to a new study published in the February 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

2 Feb 2010

Gels infused with L-arginine and Arginine heighten arousal

Give the gift of stimulation with gels infused with L-arginine and Arginine that heighten arousal and sensitivity during lovemaking. L-arginine is an amino acid. When applied to the genitals, it has been scientifically documented to increase blood flow to boost orgasms for him and her. Passion Parties' Pure Satisfaction® UniSEX Enhancement Gel is infused with L-arginine and can be used on him and her.

30 Jan 2010

Study may lead to preventative and therapeutic treatments for MS patients

Previous studies have shown multiple sclerosis (MS) patients are more often born in spring than in any other season, indicating that there is an environmental risk factor for the disease. A paper in the journal Neurology, reviewed for f1000 Medicine by Emmanuelle Waubant and Ellen Mowry, now suggests that this seasonal effect is mediated by the gene HLA-DRB1.

30 Jan 2010

Researchers use sophisticated brain-imaging techniques to predict Alzheimer's before symptoms appear

Estimates are that some 10 percent of people over the age of 65 will develop Alzheimer's disease, the scourge that robs people of their memories and, ultimately, their lives.

29 Jan 2010

UCLA researchers predict brain's progression to Alzheimer's before symptoms are visible

Estimates are that some 10 percent of people over the age of 65 will develop Alzheimer's disease, the scourge that robs people of their memories and, ultimately, their lives.

29 Jan 2010

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Regis Technologies, Inc., a leading provider of cGMP and non-GMP synthesis and separations services for active pharmaceutical ingredients (APIs) and intermediates, announced it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) stating that Regis passed the FDA’s pre-approval inspection (PAI) for its manufacture of 4-Aminopyridine the active ingredient in Ampyra™.

29 Jan 2010

Special issue explores how evolution can help doctors understand and treat diseases

What does evolution - a field that often deals with changes over many generations - have to do with preventing and treating disease in our lifetime?

28 Jan 2010

Health organizations urge Congress to protect Medicare beneficiaries' access to critical rehabilitative services

A coalition of organizations representing consumers, health professionals and providers recently sent a letter to Congressional Leadership, calling for the immediate reinstatement of the exceptions process for Medicare Part B outpatient therapy services. Without such efforts, thousands of Medicare beneficiaries will exceed arbitrary limitations on physical therapy, occupational therapy, and speech-language pathology services.

28 Jan 2010

WellWorld Science officially launches Livea in the U.S.

After more than 30 years of research and an extensive open-label weight loss study, WellWorld Science® announces the official U.S. launch of Livea®, a doctor-developed, non-prescription, patent-pending appetite-control supplement that is unlike any other dietary supplement on the market.

27 Jan 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

HTDS announces recent business developments

Study calls for individualized therapeutic interventions for MS patients

New ICD-9-CM database provides FDA-approved and off-label uses for therapeutic drugs

Immigrants may be healthier than long-term residents

Low Vision of Michigan introduces new device for RP patients

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

Sales of Nutra Pharma's Cobroxin totaled $583,955 for fourth-quarter ending December 31, 2009

Compugen discovers CGEN-15001 protein for treatment of autoimmune disorders

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Memory loss or decline in thinking abilities may indicate higher risk of stroke

Gels infused with L-arginine and Arginine heighten arousal

Study may lead to preventative and therapeutic treatments for MS patients

Researchers use sophisticated brain-imaging techniques to predict Alzheimer's before symptoms appear

UCLA researchers predict brain's progression to Alzheimer's before symptoms are visible

Regis Technologies' 4-Aminopyridine manufacturing facility receives FDA's EIR and PAI approval

Special issue explores how evolution can help doctors understand and treat diseases

Health organizations urge Congress to protect Medicare beneficiaries' access to critical rehabilitative services

WellWorld Science officially launches Livea in the U.S.

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in